Dive Brief:
- Labcorp has expanded its collaboration with PathAI to use a digital pathology platform at its anatomic pathology labs and hospital sites.
- The agreement, which Labcorp disclosed Monday, supports the use of PathAI’s AISight Dx to enable digital workflows for case management, slide review, collaboration and annotation.
- Quest Diagnostics, Labcorp’s main rival, licensed AISight Dx in 2024 in conjunction with its $100 million acquisition of PathAI’s diagnostic laboratory in Memphis, Tennessee.
Dive Insight:
Labcorp invested in PathAI in 2019 and expanded its use of the company’s technology to support clinical trials in 2021. Upon receiving the investment, PathAI said the relationship with Labcorp would advance the “eventual integration” of its artificial intelligence-enabled computational pathology tool with clinical laboratories. Almost seven years later, Labcorp is rolling AISight Dx out across its U.S. network.
AISight Dx is software for handling scanned surgical pathology slides. Using the software, pathologists review, interpret and manage digital images of slides for primary diagnosis. PathAI provides AI-powered image analysis, secure storage and system connectivity to improve turnaround times, efficiency, quality and collaboration.
PathAI received Food and Drug Administration clearance for its digital pathology platform in 2022. Under a 510(k) clearance received in 2025, PathAI can validate and implement specified major changes such as additional displays, scanners, file formats and browsers without asking the FDA.
Marcia Eisenberg, chief scientific officer at Labcorp, said in a statement that the expanded agreement will enable the company to scale digital pathology nationwide and integrate AI insights into routine care. Labcorp aims to deliver faster, more consistent results using the technology. The company’s pursuit of those goals is part of a broader push to integrate AI into its pathology operations.
At the J.P. Morgan Healthcare Conference in January, Labcorp CEO Adam Schechter said the company is looking into how to use AI at its laboratory, microbiology, cytology and pathology operations. The goal is to help identify issues much faster by equipping the pathologist “to know exactly where to look, when to look,” the CEO said. Labcorp wants to virtually stain tissues so it can process samples in multiple ways.
